Lung Clearance Index Improved in Children Ages 6-11 on Ivacaftor/Lumacaftor

Melissa75

Ivacaftor/Lumacaftor Improves Lung Clearance Index Score In Children A new phase 3 study, led by The Hospital for Sick Children […]

Read More

Orkambi Study On Children Age 6-12 With DDF508: Cystic Fibrosis Treatment

Melissa75

Results are in from a 24-week study of Orkambi (lumacaftor/ivacaftor – a medication used in cystic fibrosis treatment) in 58 children […]

Read More

Lumacaftor/Ivacaftor longer trial on Heterozygous F508del Cystic Fibrosis Patients

Melissa75

At the end of November, the results of a clinical trial of Lumacaftor/Ivacaftor, also known as Orkambi, in CF patients […]

Read More

Drug Development Pipeline for Cystic Fibrosis treatment

Melissa75

The CFF has a interesting and easy to use Drug Development Pipeline webpage which shows the stages of medication that […]

Read More

CRISPR Finds Mutated DNA and Is Okayed for Clinical Trial

Imogene

Since 2003, when we first started saving all our messages here at CysticFibrosis.com, Cystic Fibrosis genetics and our mutations have […]

Read More

Matching Volunteers to Clinical Trials by App

Imogene

  It takes on average 17 years for clinical breakthroughs in the laboratory to reach patients. A big part of […]

Read More

In the News: Inhaled Levofloxacin & QIDP Designation

Melissa75

Raptor Pharmaceutical’s MP-376 (Inhaled Levofloxacin) granted QIDP Status by the FDA on March 16, 2016. What is Qualified Infectious Disease […]

Read More

We Lobby

Imogene

A Brief History of Our Lobbying Efforts in 2015   In April, 2015, we sent this letter to the FDA […]

Read More